KR20080081359A - Ｐｐａｒ 조절제로서의 스피로 이미다졸 유도체 - Google Patents

Info

Publication number

KR20080081359A

KR20080081359A KR1020087018697A KR20087018697A KR20080081359A KR 20080081359 A KR20080081359 A KR 20080081359A KR 1020087018697 A KR1020087018697 A KR 1020087018697A KR 20087018697 A KR20087018697 A KR 20087018697A KR 20080081359 A KR20080081359 A KR 20080081359A

Authority

KR

South Korea

Prior art keywords

phenyl

spiro

dioxo

triaza

dec

Prior art date

2006-01-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims abstract description 161
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 43
• 201000010099 disease Diseases 0.000 claims abstract description 27
• 238000011282 treatment Methods 0.000 claims abstract description 22
• 230000000694 effects Effects 0.000 claims abstract description 16
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 16
• 208000035475 disorder Diseases 0.000 claims abstract description 10
• 230000002265 prevention Effects 0.000 claims abstract description 8
• 125000000217 alkyl group Chemical group 0.000 claims description 69
• 239000001257 hydrogen Substances 0.000 claims description 52
• 229910052739 hydrogen Inorganic materials 0.000 claims description 52
• -1 3-methyl-but-2-enyl Chemical group 0.000 claims description 50
• 238000000034 method Methods 0.000 claims description 46
• QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 37
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 32
• 150000003839 salts Chemical class 0.000 claims description 30
• 239000003112 inhibitor Substances 0.000 claims description 28
• 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 27
• 150000002431 hydrogen Chemical class 0.000 claims description 20
• 239000003814 drug Substances 0.000 claims description 17
• 125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 15
• 125000003545 alkoxy group Chemical group 0.000 claims description 15
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 15
• 208000002705 Glucose Intolerance Diseases 0.000 claims description 14
• 201000009104 prediabetes syndrome Diseases 0.000 claims description 14
• 239000003446 ligand Substances 0.000 claims description 13
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims description 12
• 201000001320 Atherosclerosis Diseases 0.000 claims description 11
• 239000004480 active ingredient Substances 0.000 claims description 11
• 208000002551 irritable bowel syndrome Diseases 0.000 claims description 11
• 239000011734 sodium Substances 0.000 claims description 11
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 10
• 125000000173 4-trifluoromethoxy benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC(F)(F)F)C([H])([H])* 0.000 claims description 9
• 102400000322 Glucagon-like peptide 1 Human genes 0.000 claims description 9
• 101800000224 Glucagon-like peptide 1 Proteins 0.000 claims description 9
• 229910052799 carbon Inorganic materials 0.000 claims description 9
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
• 208000035150 Hypercholesterolemia Diseases 0.000 claims description 8
• 208000024891 symptom Diseases 0.000 claims description 8
• 208000024827 Alzheimer disease Diseases 0.000 claims description 7
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 7
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 7
• 208000011231 Crohn disease Diseases 0.000 claims description 7
• 208000032928 Dyslipidaemia Diseases 0.000 claims description 7
• 208000031226 Hyperlipidaemia Diseases 0.000 claims description 7
• 206010020772 Hypertension Diseases 0.000 claims description 7
• 206010061218 Inflammation Diseases 0.000 claims description 7
• 208000017170 Lipid metabolism disease Diseases 0.000 claims description 7
• 241001465754 Metazoa Species 0.000 claims description 7
• 206010028980 Neoplasm Diseases 0.000 claims description 7
• 208000008589 Obesity Diseases 0.000 claims description 7
• 102000023984 PPAR alpha Human genes 0.000 claims description 7
• 108010015181 PPAR delta Proteins 0.000 claims description 7
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 7
• 201000011510 cancer Diseases 0.000 claims description 7
• 239000008103 glucose Substances 0.000 claims description 7
• 208000006575 hypertriglyceridemia Diseases 0.000 claims description 7
• 230000004054 inflammatory process Effects 0.000 claims description 7
• 210000003205 muscle Anatomy 0.000 claims description 7
• 235000020824 obesity Nutrition 0.000 claims description 7
• 230000007170 pathology Effects 0.000 claims description 7
• 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims description 7
• 229940002612 prodrug Drugs 0.000 claims description 7
• 239000000651 prodrug Substances 0.000 claims description 7
• 208000017520 skin disease Diseases 0.000 claims description 7
• 208000011580 syndromic disease Diseases 0.000 claims description 7
• CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 claims description 6
• UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims description 6
• 102100038495 Bile acid receptor Human genes 0.000 claims description 6
• 102000001267 GSK3 Human genes 0.000 claims description 6
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims description 6
• 206010019280 Heart failures Diseases 0.000 claims description 6
• 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 claims description 6
• 102000004877 Insulin Human genes 0.000 claims description 6
• 108090001061 Insulin Proteins 0.000 claims description 6
• 102000003729 Neprilysin Human genes 0.000 claims description 6
• 108090000028 Neprilysin Proteins 0.000 claims description 6
• PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
• 102000002072 Non-Receptor Type 1 Protein Tyrosine Phosphatase Human genes 0.000 claims description 6
• 108010015847 Non-Receptor Type 1 Protein Tyrosine Phosphatase Proteins 0.000 claims description 6
• 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims description 6
• 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims description 6
• YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims description 6
• MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims description 6
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 6
• 206010003246 arthritis Diseases 0.000 claims description 6
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 6
• 208000030533 eye disease Diseases 0.000 claims description 6
• 229940125396 insulin Drugs 0.000 claims description 6
• 102000004311 liver X receptors Human genes 0.000 claims description 6
• 108090000865 liver X receptors Proteins 0.000 claims description 6
• 238000004519 manufacturing process Methods 0.000 claims description 6
• 208000010125 myocardial infarction Diseases 0.000 claims description 6
• HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 6
• 102000005962 receptors Human genes 0.000 claims description 6
• 108020003175 receptors Proteins 0.000 claims description 6
• 208000023504 respiratory system disease Diseases 0.000 claims description 6
• 208000019553 vascular disease Diseases 0.000 claims description 6
• BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 5
• 239000004072 C09CA03 - Valsartan Substances 0.000 claims description 5
• 108010016731 PPAR gamma Proteins 0.000 claims description 5
• 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims description 5
• 229960001138 acetylsalicylic acid Drugs 0.000 claims description 5
• 125000002947 alkylene group Chemical group 0.000 claims description 5
• 125000004432 carbon atom Chemical group C* 0.000 claims description 5
• 230000004153 glucose metabolism Effects 0.000 claims description 5
• RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 5
• 229910052708 sodium Inorganic materials 0.000 claims description 5
• IKBKZGMPCYNSLU-RGVLZGJSSA-N tegaserod Chemical compound C1=C(OC)C=C2C(/C=N/NC(=N)NCCCCC)=CNC2=C1 IKBKZGMPCYNSLU-RGVLZGJSSA-N 0.000 claims description 5
• 229960002876 tegaserod Drugs 0.000 claims description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
• 229960004699 valsartan Drugs 0.000 claims description 5
• SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 5
• DBGIVFWFUFKIQN-VIFPVBQESA-N (+)-Fenfluramine Chemical compound CCN[C@@H](C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-VIFPVBQESA-N 0.000 claims description 4
• KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 claims description 4
• ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 4
• 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 claims description 4
• KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 claims description 4
• VKYGHDNEOSJZDY-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-1-[4-(4-methoxyphenyl)butyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCCCN1C2(CCN(CC2)C=2C=C(CC(O)=O)C=CC=2)C(=O)N(CC2CCC2)C1=O VKYGHDNEOSJZDY-UHFFFAOYSA-N 0.000 claims description 4
• CIDMDYCYBMLUAZ-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-2,4-dioxo-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C=CC(=CC=2)C(F)(F)F)=O)=C1 CIDMDYCYBMLUAZ-UHFFFAOYSA-N 0.000 claims description 4
• 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims description 4
• LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 4
• 206010022489 Insulin Resistance Diseases 0.000 claims description 4
• TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims description 4
• RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 4
• 102000018692 Sulfonylurea Receptors Human genes 0.000 claims description 4
• 108010091821 Sulfonylurea Receptors Proteins 0.000 claims description 4
• 125000003342 alkenyl group Chemical group 0.000 claims description 4
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
• KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 claims description 4
• 229960004597 dexfenfluramine Drugs 0.000 claims description 4
• XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 claims description 4
• 229960004890 diethylpropion Drugs 0.000 claims description 4
• LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 4
• 229960005156 digoxin Drugs 0.000 claims description 4
• LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 229960003765 fluvastatin Drugs 0.000 claims description 4
• 150000004677 hydrates Chemical class 0.000 claims description 4
• 201000001421 hyperglycemia Diseases 0.000 claims description 4
• XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 4
• 229960003105 metformin Drugs 0.000 claims description 4
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
• 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
• DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 claims description 4
• 229960002797 pitavastatin Drugs 0.000 claims description 4
• VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 claims description 4
• 229960002965 pravastatin Drugs 0.000 claims description 4
• TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims description 4
• AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol Chemical compound C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 4
• 229960002855 simvastatin Drugs 0.000 claims description 4
• RMMXLENWKUUMAY-UHFFFAOYSA-N telmisartan Chemical compound CCCC1=NC2=C(C)C=C(C=3N(C4=CC=CC=C4N=3)C)C=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C(O)=O RMMXLENWKUUMAY-UHFFFAOYSA-N 0.000 claims description 4
• XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims description 3
• VDSBXXDKCUBMQC-HNGSOEQISA-N (4r,6s)-6-[(e)-2-[2-(4-fluoro-3-methylphenyl)-4,4,6,6-tetramethylcyclohexen-1-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C1=C(F)C(C)=CC(C=2CC(C)(C)CC(C)(C)C=2\C=C\[C@H]2OC(=O)C[C@H](O)C2)=C1 VDSBXXDKCUBMQC-HNGSOEQISA-N 0.000 claims description 3
• SLYRGJDSFOCAAI-UHFFFAOYSA-N 1,3-thiazolidin-2-one Chemical class O=C1NCCS1 SLYRGJDSFOCAAI-UHFFFAOYSA-N 0.000 claims description 3
• ZZMBOAOMRSMSHR-UHFFFAOYSA-N 2-[2-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]pyrimidin-4-yl]oxy-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2N=C(OC(C)(C)C(O)=O)C=CN=2)C(=O)N(CC(C)C)C1=O ZZMBOAOMRSMSHR-UHFFFAOYSA-N 0.000 claims description 3
• JHJHAGGNGOILEV-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-2,4-dioxo-1,3-diazaspiro[4.5]decan-8-yl]phenoxy]-2-methylpropanoic acid Chemical compound OC(=O)C(C)(C)OC1=CC=CC(C2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 JHJHAGGNGOILEV-UHFFFAOYSA-N 0.000 claims description 3
• RJMACAHLXWZZBS-UHFFFAOYSA-N 2-[3-[3-(cyclopropylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CC(O)=O)C=CC=2)C(=O)N(CC2CC2)C1=O RJMACAHLXWZZBS-UHFFFAOYSA-N 0.000 claims description 3
• FGNGKQZMFALBIF-UHFFFAOYSA-N 2-[3-[3-(cyclopropylmethyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CC2)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 FGNGKQZMFALBIF-UHFFFAOYSA-N 0.000 claims description 3
• KVLLNMDOHJFOGC-UHFFFAOYSA-N 2-[3-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]sulfonyl]-4-methylphenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)S(=O)(=O)C=2C(=CC=C(CC(O)=O)C=2)C)C(=O)N(CC(C)C)C1=O KVLLNMDOHJFOGC-UHFFFAOYSA-N 0.000 claims description 3
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims description 3
• VNACOBVZDCLAEV-GXKRWWSZSA-N 6-[2-[[2-[(2s)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile;dihydrochloride Chemical compound Cl.Cl.N1([C@@H](CCC1)C#N)C(=O)CNCCNC1=CC=C(C#N)C=N1 VNACOBVZDCLAEV-GXKRWWSZSA-N 0.000 claims description 3
• UXOWGYHJODZGMF-QORCZRPOSA-N Aliskiren Chemical compound COCCCOC1=CC(C[C@@H](C[C@H](N)[C@@H](O)C[C@@H](C(C)C)C(=O)NCC(C)(C)C(N)=O)C(C)C)=CC=C1OC UXOWGYHJODZGMF-QORCZRPOSA-N 0.000 claims description 3
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims description 3
• XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims description 3
• XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims description 3
• 229940123208 Biguanide Drugs 0.000 claims description 3
• 229920001268 Cholestyramine Polymers 0.000 claims description 3
• 108010011459 Exenatide Proteins 0.000 claims description 3
• FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims description 3
• 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
• 229940122199 Insulin secretagogue Drugs 0.000 claims description 3
• 229940122355 Insulin sensitizer Drugs 0.000 claims description 3
• 239000005517 L01XE01 - Imatinib Substances 0.000 claims description 3
• PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 3
• 108090000854 Oxidoreductases Proteins 0.000 claims description 3
• 102000004316 Oxidoreductases Human genes 0.000 claims description 3
• XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 3
• AJLFOPYRIVGYMJ-UHFFFAOYSA-N SJ000287055 Natural products C12C(OC(=O)C(C)CC)CCC=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 AJLFOPYRIVGYMJ-UHFFFAOYSA-N 0.000 claims description 3
• 229940100389 Sulfonylurea Drugs 0.000 claims description 3
• 229960002632 acarbose Drugs 0.000 claims description 3
• XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims description 3
• 229960004601 aliskiren Drugs 0.000 claims description 3
• 239000003888 alpha glucosidase inhibitor Substances 0.000 claims description 3
• 229940000806 amaryl Drugs 0.000 claims description 3
• 239000003472 antidiabetic agent Substances 0.000 claims description 3
• 239000003524 antilipemic agent Substances 0.000 claims description 3
• 229960005370 atorvastatin Drugs 0.000 claims description 3
• 150000004283 biguanides Chemical class 0.000 claims description 3
• 229960005110 cerivastatin Drugs 0.000 claims description 3
• SEERZIQQUAZTOL-ANMDKAQQSA-N cerivastatin Chemical compound COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC(O)=O)=C1C1=CC=C(F)C=C1 SEERZIQQUAZTOL-ANMDKAQQSA-N 0.000 claims description 3
• GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims description 3
• JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 3
• 229950003040 dalvastatin Drugs 0.000 claims description 3
• 230000001419 dependent effect Effects 0.000 claims description 3
• 229940011871 estrogen Drugs 0.000 claims description 3
• 239000000262 estrogen Substances 0.000 claims description 3
• 229960001519 exenatide Drugs 0.000 claims description 3
• 229940125753 fibrate Drugs 0.000 claims description 3
• WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical group O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 claims description 3
• 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
• KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims description 3
• 229960002411 imatinib Drugs 0.000 claims description 3
• 229960004844 lovastatin Drugs 0.000 claims description 3
• PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 3
• QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 3
• 229950004994 meglitinide Drugs 0.000 claims description 3
• AJLFOPYRIVGYMJ-INTXDZFKSA-N mevastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=CCC[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 AJLFOPYRIVGYMJ-INTXDZFKSA-N 0.000 claims description 3
• 229950009116 mevastatin Drugs 0.000 claims description 3
• BOZILQFLQYBIIY-UHFFFAOYSA-N mevastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CCC=C21 BOZILQFLQYBIIY-UHFFFAOYSA-N 0.000 claims description 3
• 229960000698 nateglinide Drugs 0.000 claims description 3
• OELFLUMRDSZNSF-BRWVUGGUSA-N nateglinide Chemical compound C1C[C@@H](C(C)C)CC[C@@H]1C(=O)N[C@@H](C(O)=O)CC1=CC=CC=C1 OELFLUMRDSZNSF-BRWVUGGUSA-N 0.000 claims description 3
• 229960003512 nicotinic acid Drugs 0.000 claims description 3
• 235000001968 nicotinic acid Nutrition 0.000 claims description 3
• 239000011664 nicotinic acid Substances 0.000 claims description 3
• AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims description 3
• 229960001243 orlistat Drugs 0.000 claims description 3
• 229960005095 pioglitazone Drugs 0.000 claims description 3
• 229960002354 repaglinide Drugs 0.000 claims description 3
• 229960004586 rosiglitazone Drugs 0.000 claims description 3
• 229960000672 rosuvastatin Drugs 0.000 claims description 3
• BPRHUIZQVSMCRT-VEUZHWNKSA-N rosuvastatin Chemical compound CC(C)C1=NC(N(C)S(C)(=O)=O)=NC(C=2C=CC(F)=CC=2)=C1\C=C\[C@@H](O)C[C@@H](O)CC(O)=O BPRHUIZQVSMCRT-VEUZHWNKSA-N 0.000 claims description 3
• 230000003248 secreting effect Effects 0.000 claims description 3
• 239000000849 selective androgen receptor modulator Substances 0.000 claims description 3
• 239000000333 selective estrogen receptor modulator Substances 0.000 claims description 3
• 229940095743 selective estrogen receptor modulator Drugs 0.000 claims description 3
• 239000012453 solvate Substances 0.000 claims description 3
• 239000004059 squalene synthase inhibitor Substances 0.000 claims description 3
• 229960003604 testosterone Drugs 0.000 claims description 3
• DBGIVFWFUFKIQN-UHFFFAOYSA-N (+-)-Fenfluramine Chemical compound CCNC(C)CC1=CC=CC(C(F)(F)F)=C1 DBGIVFWFUFKIQN-UHFFFAOYSA-N 0.000 claims description 2
• BOOOLEGQBVUTKC-NVQSDHBMSA-N (2e,4e)-3-methyl-5-[(1s,2s)-2-methyl-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)cyclopropyl]penta-2,4-dienoic acid Chemical compound OC(=O)\C=C(/C)\C=C\[C@@H]1C[C@]1(C)C1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BOOOLEGQBVUTKC-NVQSDHBMSA-N 0.000 claims description 2
• KVVODNUBDFULSC-XMMPIXPASA-N (2r)-1-[4-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-oxazol-4-yl]methoxy]phenyl]sulfonyl-2,3-dihydroindole-2-carboxylic acid Chemical compound N=1C(COC=2C=CC(=CC=2)S(=O)(=O)N2C3=CC=CC=C3C[C@@H]2C(O)=O)=C(C)OC=1C1=CC=C(C(F)(F)F)C=C1 KVVODNUBDFULSC-XMMPIXPASA-N 0.000 claims description 2
• FONCZICQWCUXEB-RUZDIDTESA-N (2r)-2-[4-(9-bromo-2,3-dimethylbenzo[f][1]benzothiol-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid Chemical compound C([C@@H](OC1=C(C)C=C(C=C1C)C=1C2=CC=CC=C2C(Br)=C2SC(=C(C2=1)C)C)C(O)=O)C1=CC=CC=C1 FONCZICQWCUXEB-RUZDIDTESA-N 0.000 claims description 2
• LPUDGHQMOAHMMF-JBACZVJFSA-N (2s)-2-[[[(2s)-6-amino-2-(methanesulfonamido)hexanoyl]amino]methyl]-3-[1-[[(1s)-1-carboxy-2-(4-hydroxyphenyl)ethyl]carbamoyl]cyclopentyl]propanoic acid Chemical compound N([C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C(=O)C1(C[C@@H](CNC(=O)[C@H](CCCCN)NS(=O)(=O)C)C(O)=O)CCCC1 LPUDGHQMOAHMMF-JBACZVJFSA-N 0.000 claims description 2
• BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 claims description 2
• METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
• RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims description 2
• TWBNMYSKRDRHAT-RCWTXCDDSA-N (S)-timolol hemihydrate Chemical compound O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 TWBNMYSKRDRHAT-RCWTXCDDSA-N 0.000 claims description 2
• SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
• XMQODGUTLZXUGZ-RPBOFIJWSA-N 2-[(3s)-3-[[1-[(2r)-2-ethoxycarbonyl-4-phenylbutyl]cyclopentanecarbonyl]amino]-2-oxo-4,5-dihydro-3h-1-benzazepin-1-yl]acetic acid Chemical compound C([C@@H](C(=O)OCC)CC1(CCCC1)C(=O)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XMQODGUTLZXUGZ-RPBOFIJWSA-N 0.000 claims description 2
• UEZLELPZUPWZCK-UHFFFAOYSA-N 2-[2,3-difluoro-5-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(OC(C)(C)C(O)=O)C(F)=C(F)C=2)C(=O)N(CC(C)C)C1=O UEZLELPZUPWZCK-UHFFFAOYSA-N 0.000 claims description 2
• OHNNGJYQWKHBRR-UHFFFAOYSA-N 2-[2-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]pyridin-4-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2N=CC=C(CC(O)=O)C=2)C(=O)N(CC(C)C)C1=O OHNNGJYQWKHBRR-UHFFFAOYSA-N 0.000 claims description 2
• RPIBNLNWBVLIFV-UHFFFAOYSA-N 2-[2-chloro-5-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(OC(C)(C)C(O)=O)C(Cl)=CC=2)C(=O)N(CC(C)C)C1=O RPIBNLNWBVLIFV-UHFFFAOYSA-N 0.000 claims description 2
• PEUGKBSPXVAKTP-UHFFFAOYSA-N 2-[2-chloro-5-[3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenoxy]-2-methylpropanoic acid Chemical compound C1=C(Cl)C(OC(C)(C)C(O)=O)=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 PEUGKBSPXVAKTP-UHFFFAOYSA-N 0.000 claims description 2
• UKPGJBRTVUONSL-UHFFFAOYSA-N 2-[2-chloro-5-[3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenoxy]acetic acid Chemical compound C1=C(Cl)C(OCC(=O)O)=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 UKPGJBRTVUONSL-UHFFFAOYSA-N 0.000 claims description 2
• WIXLBDYBSUFJSL-UHFFFAOYSA-N 2-[2-fluoro-5-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CC(O)=O)C(F)=CC=2)C(=O)N(CC(C)C)C1=O WIXLBDYBSUFJSL-UHFFFAOYSA-N 0.000 claims description 2
• HFFFOWBZCUQNAE-UHFFFAOYSA-N 2-[3-[1-[(2,4-dichloro-5-fluorophenyl)methyl]-3-(3,3-dimethylbutyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCC(C)(C)C)C(=O)N2CC1=CC(F)=C(Cl)C=C1Cl HFFFOWBZCUQNAE-UHFFFAOYSA-N 0.000 claims description 2
• RAJCGAGVAUIDDR-UHFFFAOYSA-N 2-[3-[1-[(2,4-dichloro-5-fluorophenyl)methyl]-3-(4-fluorobutyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CCCCF)C(=O)N3CC=2C(=CC(Cl)=C(F)C=2)Cl)=O)=C1 RAJCGAGVAUIDDR-UHFFFAOYSA-N 0.000 claims description 2
• YMDTXODYLHUFQL-UHFFFAOYSA-N 2-[3-[1-[2-(4-bromophenyl)-2-hydroxyethyl]-3-(3-methylbutyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCC(C)C)C(=O)N2CC(O)C1=CC=C(Br)C=C1 YMDTXODYLHUFQL-UHFFFAOYSA-N 0.000 claims description 2
• XPTXXKKFSRNKDM-UHFFFAOYSA-N 2-[3-[1-[2-(4-chlorophenyl)-2-hydroxyethyl]-3-(3-methylbutyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCC(C)C)C(=O)N2CC(O)C1=CC=C(Cl)C=C1 XPTXXKKFSRNKDM-UHFFFAOYSA-N 0.000 claims description 2
• ZEBJESQXZYGDJW-UHFFFAOYSA-N 2-[3-[1-[2-(4-chlorophenyl)ethyl]-3-(cyclopentylmethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCCC2)C(=O)N3CCC=2C=CC(Cl)=CC=2)=O)=C1 ZEBJESQXZYGDJW-UHFFFAOYSA-N 0.000 claims description 2
• OUWDKDIHVKPDKZ-UHFFFAOYSA-N 2-[3-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(C=CC=2)C(C)(C)C(O)=O)C(=O)N(CC(C)C)C1=O OUWDKDIHVKPDKZ-UHFFFAOYSA-N 0.000 claims description 2
• NZNMGZMMMDAGAJ-UHFFFAOYSA-N 2-[3-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2-oxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CC(O)=O)C=CC=2)CN(CC(C)C)C1=O NZNMGZMMMDAGAJ-UHFFFAOYSA-N 0.000 claims description 2
• PKDJTGGWUXEANA-UHFFFAOYSA-N 2-[3-[1-[2-(4-methoxyphenyl)ethyl]-3-(3-methylbutyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CC(O)=O)C=CC=2)C(=O)N(CCC(C)C)C1=O PKDJTGGWUXEANA-UHFFFAOYSA-N 0.000 claims description 2
• OJVAPBGDYDJUGX-UHFFFAOYSA-N 2-[3-[1-[[2,4-bis(trifluoromethyl)phenyl]methyl]-3-(cyclopentylmethyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCCC2)C(=O)N3CC=2C(=CC(=CC=2)C(F)(F)F)C(F)(F)F)=O)=C1 OJVAPBGDYDJUGX-UHFFFAOYSA-N 0.000 claims description 2
• TXYUUIHTPSUWEJ-UHFFFAOYSA-N 2-[3-[2,4-dioxo-3-(3,4,4-trifluorobut-3-enyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CCC(F)=C(F)F)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 TXYUUIHTPSUWEJ-UHFFFAOYSA-N 0.000 claims description 2
• DYXGXSZGMLKQOG-UHFFFAOYSA-N 2-[3-[2,4-dioxo-3-(3-pyrrol-1-ylpropyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CCCN2C=CC=C2)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 DYXGXSZGMLKQOG-UHFFFAOYSA-N 0.000 claims description 2
• BOCVHTPGGNHGFN-UHFFFAOYSA-N 2-[3-[2,4-dioxo-3-(4,4,4-trifluorobutyl)-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CCCC(F)(F)F)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 BOCVHTPGGNHGFN-UHFFFAOYSA-N 0.000 claims description 2
• FZDPRJFOIDIJFF-UHFFFAOYSA-N 2-[3-[2,4-dioxo-3-pentyl-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCCCC)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 FZDPRJFOIDIJFF-UHFFFAOYSA-N 0.000 claims description 2
• MQTGPNNUWPEVHB-UHFFFAOYSA-N 2-[3-[3-(2-ethylbutyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CC(CC)CC)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 MQTGPNNUWPEVHB-UHFFFAOYSA-N 0.000 claims description 2
• JUQPKCIHLUIJIH-UHFFFAOYSA-N 2-[3-[3-(2-ethylhexyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CC(CC)CCCC)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 JUQPKCIHLUIJIH-UHFFFAOYSA-N 0.000 claims description 2
• SIKSBRZTYJGZQZ-UHFFFAOYSA-N 2-[3-[3-(2-methylbutyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CC(C)CC)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 SIKSBRZTYJGZQZ-UHFFFAOYSA-N 0.000 claims description 2
• UDJZFAORMWOELP-UHFFFAOYSA-N 2-[3-[3-(2-methylpropyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CC(C)C)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 UDJZFAORMWOELP-UHFFFAOYSA-N 0.000 claims description 2
• LGGNMVOCVQVVLH-UHFFFAOYSA-N 2-[3-[3-(3,3-dimethyl-2-oxobutyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CC(=O)C(C)(C)C)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 LGGNMVOCVQVVLH-UHFFFAOYSA-N 0.000 claims description 2
• ZTVSUNLDDIYPHX-UHFFFAOYSA-N 2-[3-[3-(3,3-dimethylbutyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCC(C)(C)C)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 ZTVSUNLDDIYPHX-UHFFFAOYSA-N 0.000 claims description 2
• WOFDRDSCGQXSQZ-UHFFFAOYSA-N 2-[3-[3-(3-methylbut-2-enyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CC=C(C)C)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 WOFDRDSCGQXSQZ-UHFFFAOYSA-N 0.000 claims description 2
• XXZJDDYGUUZKFG-UHFFFAOYSA-N 2-[3-[3-(4-methylpentyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCCC(C)C)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 XXZJDDYGUUZKFG-UHFFFAOYSA-N 0.000 claims description 2
• FMPAJMIKTPEIFX-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 FMPAJMIKTPEIFX-UHFFFAOYSA-N 0.000 claims description 2
• HRSNJCOCLKVCEK-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CC(O)=O)C=CC=2)C(=O)N(CC2CCC2)C1=O HRSNJCOCLKVCEK-UHFFFAOYSA-N 0.000 claims description 2
• QBFLFTMMFWFCSR-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-2,4-dioxo-1-[[3-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CC=2C=C(OC(F)(F)F)C=CC=2)=O)=C1 QBFLFTMMFWFCSR-UHFFFAOYSA-N 0.000 claims description 2
• XREOGMZLCKTBGV-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 XREOGMZLCKTBGV-UHFFFAOYSA-N 0.000 claims description 2
• UFJBBDSYIWELNW-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-2,4-dioxo-1-[[4-(trifluoromethyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CC=2C=CC(=CC=2)C(F)(F)F)=O)=C1 UFJBBDSYIWELNW-UHFFFAOYSA-N 0.000 claims description 2
• UTQIHCCIFJTOIP-UHFFFAOYSA-N 2-[3-[3-(cyclobutylmethyl)-2,4-dioxo-1-[[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CC=2SC=C(N=2)C=2C=CC(=CC=2)C(F)(F)F)=O)=C1 UTQIHCCIFJTOIP-UHFFFAOYSA-N 0.000 claims description 2
• FLYSWYBZHYFLTI-UHFFFAOYSA-N 2-[3-[3-(cyclohexylmethyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCCCC2)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 FLYSWYBZHYFLTI-UHFFFAOYSA-N 0.000 claims description 2
• WPBIEOPFXNPODE-UHFFFAOYSA-N 2-[3-[3-(cyclopentylmethyl)-2,4-dioxo-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCCC2)C(=O)N3CCC=2C=CC(=CC=2)C(F)(F)F)=O)=C1 WPBIEOPFXNPODE-UHFFFAOYSA-N 0.000 claims description 2
• TXRNTUBGRMENQH-UHFFFAOYSA-N 2-[3-[3-(cyclopentylmethyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCCC2)C(=O)N3CC=2C=CC(OC(F)(F)F)=CC=2)=O)=C1 TXRNTUBGRMENQH-UHFFFAOYSA-N 0.000 claims description 2
• VFWREUFTQDUNHC-UHFFFAOYSA-N 2-[3-[3-(cyclopentylmethyl)-2,4-dioxo-1-[[4-(trifluoromethyl)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCCC2)C(=O)N3CC=2C=CC(=CC=2)C(F)(F)F)=O)=C1 VFWREUFTQDUNHC-UHFFFAOYSA-N 0.000 claims description 2
• XNSXNFSQSKTMLV-UHFFFAOYSA-N 2-[3-[3-(cyclopropylmethyl)-2,4-dioxo-1-[[4-[4-(trifluoromethyl)phenyl]-1,3-thiazol-2-yl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CC2)C(=O)N3CC=2SC=C(N=2)C=2C=CC(=CC=2)C(F)(F)F)=O)=C1 XNSXNFSQSKTMLV-UHFFFAOYSA-N 0.000 claims description 2
• XAKHEDWSRRHIGB-UHFFFAOYSA-N 2-[3-[3-butyl-1-[2-(4-methoxyphenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetic acid Chemical compound C1CN(C=2C=C(CC(O)=O)C=CC=2)CCC21C(=O)N(CCCC)C(=O)N2CCC1=CC=C(OC)C=C1 XAKHEDWSRRHIGB-UHFFFAOYSA-N 0.000 claims description 2
• CMMVHYCBDQLMLK-UHFFFAOYSA-N 2-[3-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]methyl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC=3C=C(CC(O)=O)C=CC=3)CC2)C(=O)N(CC(C)C)C1=O CMMVHYCBDQLMLK-UHFFFAOYSA-N 0.000 claims description 2
• HIUCRQAKGVFBPT-UHFFFAOYSA-N 2-[4-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]pyrimidin-2-yl]oxy-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2N=C(OC(C)(C)C(O)=O)N=CC=2)C(=O)N(CC(C)C)C1=O HIUCRQAKGVFBPT-UHFFFAOYSA-N 0.000 claims description 2
• UIRRIAVUQMXRNY-UHFFFAOYSA-N 2-[4-methoxy-3-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]sulfonyl]phenyl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)S(=O)(=O)C=2C(=CC=C(CC(O)=O)C=2)OC)C(=O)N(CC(C)C)C1=O UIRRIAVUQMXRNY-UHFFFAOYSA-N 0.000 claims description 2
• JSCMFYGKFCRFFG-UHFFFAOYSA-N 2-[5-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-2-methylphenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(OC(C)(C)C(O)=O)C(C)=CC=2)C(=O)N(CC(C)C)C1=O JSCMFYGKFCRFFG-UHFFFAOYSA-N 0.000 claims description 2
• SSCAHJNDKSPDTG-UHFFFAOYSA-N 2-[5-[3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]-2-methylphenyl]acetic acid Chemical compound C1=C(CC(O)=O)C(C)=CC=C1N1CCC2(C(N(CC3CCC3)C(=O)N2CCC=2C(=CC(Cl)=CC=2)Cl)=O)CC1 SSCAHJNDKSPDTG-UHFFFAOYSA-N 0.000 claims description 2
• KJDBOMMTVCNIFH-UHFFFAOYSA-N 2-[6-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]pyridin-2-yl]acetic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2N=C(CC(O)=O)C=CC=2)C(=O)N(CC(C)C)C1=O KJDBOMMTVCNIFH-UHFFFAOYSA-N 0.000 claims description 2
• HLDVOPDBOZMPDE-UHFFFAOYSA-N 2-[6-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]pyrimidin-4-yl]oxy-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2N=CN=C(OC(C)(C)C(O)=O)C=2)C(=O)N(CC(C)C)C1=O HLDVOPDBOZMPDE-UHFFFAOYSA-N 0.000 claims description 2
• LWPUILAXAKJMJO-UHFFFAOYSA-N 2-[6-[3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]pyridin-2-yl]acetic acid Chemical compound OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=N1 LWPUILAXAKJMJO-UHFFFAOYSA-N 0.000 claims description 2
• 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
• FWWOWPGPERBCNJ-UHFFFAOYSA-N 2-hydroxy-4-(2-hydroxyethoxy)-4-oxobutanoic acid Chemical compound OCCOC(=O)CC(O)C(O)=O FWWOWPGPERBCNJ-UHFFFAOYSA-N 0.000 claims description 2
• 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 claims description 2
• 125000005916 2-methylpentyl group Chemical group 0.000 claims description 2
• QSRGRMTYCSJIBU-UHFFFAOYSA-N 3-[3-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]propanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CCC(O)=O)C=CC=2)C(=O)N(CC(C)C)C1=O QSRGRMTYCSJIBU-UHFFFAOYSA-N 0.000 claims description 2
• HSWIOROMWRTAJG-UHFFFAOYSA-N 3-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]methyl]benzoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC=3C=C(C=CC=3)C(O)=O)CC2)C(=O)N(CC(C)C)C1=O HSWIOROMWRTAJG-UHFFFAOYSA-N 0.000 claims description 2
• UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
• NKOHRVBBQISBSB-UHFFFAOYSA-N 5-[(4-hydroxyphenyl)methyl]-1,3-thiazolidine-2,4-dione Chemical compound C1=CC(O)=CC=C1CC1C(=O)NC(=O)S1 NKOHRVBBQISBSB-UHFFFAOYSA-N 0.000 claims description 2
• RZTAMFZIAATZDJ-HNNXBMFYSA-N 5-o-ethyl 3-o-methyl (4s)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC(Cl)=C1Cl RZTAMFZIAATZDJ-HNNXBMFYSA-N 0.000 claims description 2
• JBMKAUGHUNFTOL-UHFFFAOYSA-N Aldoclor Chemical class C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NC=NS2(=O)=O JBMKAUGHUNFTOL-UHFFFAOYSA-N 0.000 claims description 2
• PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 claims description 2
• PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims description 2
• 229940123338 Aldosterone synthase inhibitor Drugs 0.000 claims description 2
• 229940123413 Angiotensin II antagonist Drugs 0.000 claims description 2
• 208000000103 Anorexia Nervosa Diseases 0.000 claims description 2
• 102000005666 Apolipoprotein A-I Human genes 0.000 claims description 2
• 108010059886 Apolipoprotein A-I Proteins 0.000 claims description 2
• XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 claims description 2
• 208000032841 Bulimia Diseases 0.000 claims description 2
• 206010006550 Bulimia nervosa Diseases 0.000 claims description 2
• 239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
• 239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
• 239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
• 239000002053 C09CA06 - Candesartan Substances 0.000 claims description 2
• 239000005537 C09CA07 - Telmisartan Substances 0.000 claims description 2
• 206010006895 Cachexia Diseases 0.000 claims description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
• 229940122820 Cannabinoid receptor antagonist Drugs 0.000 claims description 2
• JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 2
• 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 claims description 2
• 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 claims description 2
• JRWZLRBJNMZMFE-UHFFFAOYSA-N Dobutamine Chemical compound C=1C=C(O)C(O)=CC=1CCNC(C)CCC1=CC=C(O)C=C1 JRWZLRBJNMZMFE-UHFFFAOYSA-N 0.000 claims description 2
• 108010061435 Enalapril Proteins 0.000 claims description 2
• 108010046163 Glycogen Phosphorylase Proteins 0.000 claims description 2
• 102000007390 Glycogen Phosphorylase Human genes 0.000 claims description 2
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
• 102000016267 Leptin Human genes 0.000 claims description 2
• 108010092277 Leptin Proteins 0.000 claims description 2
• 102000029749 Microtubule Human genes 0.000 claims description 2
• 108091022875 Microtubule Proteins 0.000 claims description 2
• 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims description 2
• 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims description 2
• UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 claims description 2
• ZBBHBTPTTSWHBA-UHFFFAOYSA-N Nicardipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCCN(C)CC=2C=CC=CC=2)C1C1=CC=CC([N+]([O-])=O)=C1 ZBBHBTPTTSWHBA-UHFFFAOYSA-N 0.000 claims description 2
• 108010055723 PDGF receptor tyrosine kinase Proteins 0.000 claims description 2
• 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims description 2
• 102000001253 Protein Kinase Human genes 0.000 claims description 2
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 claims description 2
• 102000003673 Symporters Human genes 0.000 claims description 2
• 108090000088 Symporters Proteins 0.000 claims description 2
• 108010036928 Thiorphan Proteins 0.000 claims description 2
• 229940122388 Thrombin inhibitor Drugs 0.000 claims description 2
• KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 claims description 2
• 239000000365 Topoisomerase I Inhibitor Substances 0.000 claims description 2
• 239000000317 Topoisomerase II Inhibitor Substances 0.000 claims description 2
• NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims description 2
• VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 claims description 2
• 229960002122 acebutolol Drugs 0.000 claims description 2
• GOEMGAFJFRBGGG-UHFFFAOYSA-N acebutolol Chemical compound CCCC(=O)NC1=CC=C(OCC(O)CNC(C)C)C(C(C)=O)=C1 GOEMGAFJFRBGGG-UHFFFAOYSA-N 0.000 claims description 2
• 229960002478 aldosterone Drugs 0.000 claims description 2
• 239000002168 alkylating agent Substances 0.000 claims description 2
• 229940100198 alkylating agent Drugs 0.000 claims description 2
• HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 claims description 2
• 229960000528 amlodipine Drugs 0.000 claims description 2
• 229940025084 amphetamine Drugs 0.000 claims description 2
• 239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 2
• 208000022531 anorexia Diseases 0.000 claims description 2
• 229940046836 anti-estrogen Drugs 0.000 claims description 2
• 230000001833 anti-estrogenic effect Effects 0.000 claims description 2
• 230000000118 anti-neoplastic effect Effects 0.000 claims description 2
• 230000003579 anti-obesity Effects 0.000 claims description 2
• 229940125708 antidiabetic agent Drugs 0.000 claims description 2
• 229940030600 antihypertensive agent Drugs 0.000 claims description 2
• 239000002220 antihypertensive agent Substances 0.000 claims description 2
• 239000002256 antimetabolite Substances 0.000 claims description 2
• 229940034982 antineoplastic agent Drugs 0.000 claims description 2
• 239000002246 antineoplastic agent Substances 0.000 claims description 2
• 229940127218 antiplatelet drug Drugs 0.000 claims description 2
• 230000036528 appetite Effects 0.000 claims description 2
• 235000019789 appetite Nutrition 0.000 claims description 2
• 239000003886 aromatase inhibitor Substances 0.000 claims description 2
• 229940046844 aromatase inhibitors Drugs 0.000 claims description 2
• 229960002274 atenolol Drugs 0.000 claims description 2
• 229960004530 benazepril Drugs 0.000 claims description 2
• 229950003745 benzfetamine Drugs 0.000 claims description 2
• YXKTVDFXDRQTKV-HNNXBMFYSA-N benzphetamine Chemical compound C([C@H](C)N(C)CC=1C=CC=CC=1)C1=CC=CC=C1 YXKTVDFXDRQTKV-HNNXBMFYSA-N 0.000 claims description 2
• UIEATEWHFDRYRU-UHFFFAOYSA-N bepridil Chemical compound C1CCCN1C(COCC(C)C)CN(C=1C=CC=CC=1)CC1=CC=CC=C1 UIEATEWHFDRYRU-UHFFFAOYSA-N 0.000 claims description 2
• 229960003665 bepridil Drugs 0.000 claims description 2
• 102000012740 beta Adrenergic Receptors Human genes 0.000 claims description 2
• 108010079452 beta Adrenergic Receptors Proteins 0.000 claims description 2
• 229960004324 betaxolol Drugs 0.000 claims description 2
• CHDPSNLJFOQTRK-UHFFFAOYSA-N betaxolol hydrochloride Chemical compound [Cl-].C1=CC(OCC(O)C[NH2+]C(C)C)=CC=C1CCOCC1CC1 CHDPSNLJFOQTRK-UHFFFAOYSA-N 0.000 claims description 2
• 229960002781 bisoprolol Drugs 0.000 claims description 2
• VHYCDWMUTMEGQY-UHFFFAOYSA-N bisoprolol Chemical compound CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1 VHYCDWMUTMEGQY-UHFFFAOYSA-N 0.000 claims description 2
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 2
• 229960002802 bromocriptine Drugs 0.000 claims description 2
• SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
• 229960001058 bupropion Drugs 0.000 claims description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 239000000480 calcium channel blocker Substances 0.000 claims description 2
• 229960000932 candesartan Drugs 0.000 claims description 2
• SGZAIDDFHDDFJU-UHFFFAOYSA-N candesartan Chemical compound CCOC1=NC2=CC=CC(C(O)=O)=C2N1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SGZAIDDFHDDFJU-UHFFFAOYSA-N 0.000 claims description 2
• 239000003536 cannabinoid receptor antagonist Substances 0.000 claims description 2
• 229960000830 captopril Drugs 0.000 claims description 2
• FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
• 230000001906 cholesterol absorption Effects 0.000 claims description 2
• DCSUBABJRXZOMT-IRLDBZIGSA-N cisapride Chemical compound C([C@@H]([C@@H](CC1)NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)OC)N1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-IRLDBZIGSA-N 0.000 claims description 2
• 229960005132 cisapride Drugs 0.000 claims description 2
• DCSUBABJRXZOMT-UHFFFAOYSA-N cisapride Natural products C1CC(NC(=O)C=2C(=CC(N)=C(Cl)C=2)OC)C(OC)CN1CCCOC1=CC=C(F)C=C1 DCSUBABJRXZOMT-UHFFFAOYSA-N 0.000 claims description 2
• GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
• 229960003958 clopidogrel bisulfate Drugs 0.000 claims description 2
• 230000008602 contraction Effects 0.000 claims description 2
• 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 2
• 125000004210 cyclohexylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
• 125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 claims description 2
• 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 2
• 229940127089 cytotoxic agent Drugs 0.000 claims description 2
• 206010061428 decreased appetite Diseases 0.000 claims description 2
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
• 229960004166 diltiazem Drugs 0.000 claims description 2
• 239000002934 diuretic Substances 0.000 claims description 2
• 229940030606 diuretics Drugs 0.000 claims description 2
• DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 claims description 2
• 229960001089 dobutamine Drugs 0.000 claims description 2
• 229960000873 enalapril Drugs 0.000 claims description 2
• GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 claims description 2
• 229960002179 ephedrine Drugs 0.000 claims description 2
• JUKPWJGBANNWMW-VWBFHTRKSA-N eplerenone Chemical compound C([C@@H]1[C@]2(C)C[C@H]3O[C@]33[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)C(=O)OC)C[C@@]21CCC(=O)O1 JUKPWJGBANNWMW-VWBFHTRKSA-N 0.000 claims description 2
• 229960001208 eplerenone Drugs 0.000 claims description 2
• 229960004563 eprosartan Drugs 0.000 claims description 2
• OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
• 239000000328 estrogen antagonist Substances 0.000 claims description 2
• AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims description 2
• 229960003199 etacrynic acid Drugs 0.000 claims description 2
• OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 2
• 229960003580 felodipine Drugs 0.000 claims description 2
• 229940087476 femara Drugs 0.000 claims description 2
• 229960001582 fenfluramine Drugs 0.000 claims description 2
• 229960002464 fluoxetine Drugs 0.000 claims description 2
• 229960002490 fosinopril Drugs 0.000 claims description 2
• 229960003883 furosemide Drugs 0.000 claims description 2
• ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 2
• 229960004580 glibenclamide Drugs 0.000 claims description 2
• 229960001381 glipizide Drugs 0.000 claims description 2
• ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 claims description 2
• ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims description 2
• 229960002003 hydrochlorothiazide Drugs 0.000 claims description 2
• 229960002198 irbesartan Drugs 0.000 claims description 2
• YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 2
• 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
• NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims description 2
• 229940039781 leptin Drugs 0.000 claims description 2
• HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 claims description 2
• 230000007774 longterm Effects 0.000 claims description 2
• 239000002171 loop diuretic Substances 0.000 claims description 2
• 229960004773 losartan Drugs 0.000 claims description 2
• KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
• 239000012528 membrane Substances 0.000 claims description 2
• VKQFCGNPDRICFG-UHFFFAOYSA-N methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+]([O-])=O VKQFCGNPDRICFG-UHFFFAOYSA-N 0.000 claims description 2
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
• 229960002237 metoprolol Drugs 0.000 claims description 2
• IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
• 210000004688 microtubule Anatomy 0.000 claims description 2
• 239000003607 modifier Substances 0.000 claims description 2
• 229960005170 moexipril Drugs 0.000 claims description 2
• 230000004220 muscle function Effects 0.000 claims description 2
• 229960004255 nadolol Drugs 0.000 claims description 2
• VWPOSFSPZNDTMJ-UCWKZMIHSA-N nadolol Chemical compound C1[C@@H](O)[C@@H](O)CC2=C1C=CC=C2OCC(O)CNC(C)(C)C VWPOSFSPZNDTMJ-UCWKZMIHSA-N 0.000 claims description 2
• 229960001783 nicardipine Drugs 0.000 claims description 2
• HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 claims description 2
• 229960001597 nifedipine Drugs 0.000 claims description 2
• HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims description 2
• 229960000715 nimodipine Drugs 0.000 claims description 2
• 229960000227 nisoldipine Drugs 0.000 claims description 2
• LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims description 2
• 229950000973 omapatrilat Drugs 0.000 claims description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
• 229960003562 phentermine Drugs 0.000 claims description 2
• DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 claims description 2
• 229960000395 phenylpropanolamine Drugs 0.000 claims description 2
• 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
• BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 2
• NPUSXSOBPNHOPH-UHFFFAOYSA-N propan-2-yl 4-(2-chlorophenyl)-1-ethyl-2-methyl-5-oxo-4,7-dihydrofuro[3,4-b]pyridine-3-carboxylate Chemical compound CC(C)OC(=O)C1=C(C)N(CC)C(COC2=O)=C2C1C1=CC=CC=C1Cl NPUSXSOBPNHOPH-UHFFFAOYSA-N 0.000 claims description 2
• 229960003712 propranolol Drugs 0.000 claims description 2
• 108060006633 protein kinase Proteins 0.000 claims description 2
• 229960003908 pseudoephedrine Drugs 0.000 claims description 2
• KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 claims description 2
• 229960001455 quinapril Drugs 0.000 claims description 2
• JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 claims description 2
• 229960003401 ramipril Drugs 0.000 claims description 2
• HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 claims description 2
• 239000002464 receptor antagonist Substances 0.000 claims description 2
• 229940044551 receptor antagonist Drugs 0.000 claims description 2
• 239000002461 renin inhibitor Substances 0.000 claims description 2
• 229940086526 renin-inhibitors Drugs 0.000 claims description 2
• 229950001780 sampatrilat Drugs 0.000 claims description 2
• 229960004937 saxagliptin Drugs 0.000 claims description 2
• 108010033693 saxagliptin Proteins 0.000 claims description 2
• QGJUIPDUBHWZPV-SGTAVMJGSA-N saxagliptin Chemical compound C1C(C2)CC(C3)CC2(O)CC13[C@H](N)C(=O)N1[C@H](C#N)C[C@@H]2C[C@@H]21 QGJUIPDUBHWZPV-SGTAVMJGSA-N 0.000 claims description 2
• UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 claims description 2
• 229960004425 sibutramine Drugs 0.000 claims description 2
• 229960002370 sotalol Drugs 0.000 claims description 2
• ZBMZVLHSJCTVON-UHFFFAOYSA-N sotalol Chemical compound CC(C)NCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 ZBMZVLHSJCTVON-UHFFFAOYSA-N 0.000 claims description 2
• 230000002195 synergetic effect Effects 0.000 claims description 2
• 229960005187 telmisartan Drugs 0.000 claims description 2
• 229940083085 thiazide derivative acting on arteriolar smooth muscle Drugs 0.000 claims description 2
• LJJKNPQAGWVLDQ-SNVBAGLBSA-N thiorphan Chemical compound OC(=O)CNC(=O)[C@@H](CS)CC1=CC=CC=C1 LJJKNPQAGWVLDQ-SNVBAGLBSA-N 0.000 claims description 2
• 239000003868 thrombin inhibitor Substances 0.000 claims description 2
• 229960004605 timolol Drugs 0.000 claims description 2
• 229960004394 topiramate Drugs 0.000 claims description 2
• 229960005461 torasemide Drugs 0.000 claims description 2
• 229960002051 trandolapril Drugs 0.000 claims description 2
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
• 229960001722 verapamil Drugs 0.000 claims description 2
• 229940051223 zetia Drugs 0.000 claims description 2
• 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 8
• 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 8
• 125000001475 halogen functional group Chemical group 0.000 claims 6
• 229940124213 Dipeptidyl peptidase 4 (DPP IV) inhibitor Drugs 0.000 claims 1
• 230000007423 decrease Effects 0.000 claims 1
• 230000003247 decreasing effect Effects 0.000 claims 1
• 239000003603 dipeptidyl peptidase IV inhibitor Substances 0.000 claims 1
• 238000012423 maintenance Methods 0.000 claims 1
• 230000003387 muscular Effects 0.000 claims 1
• 239000000203 mixture Substances 0.000 description 77
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 73
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 64
• 239000000543 intermediate Substances 0.000 description 56
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
• 235000019439 ethyl acetate Nutrition 0.000 description 35
• 239000000243 solution Substances 0.000 description 35
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 34
• 238000006243 chemical reaction Methods 0.000 description 31
• 239000012044 organic layer Substances 0.000 description 31
• 239000011541 reaction mixture Substances 0.000 description 31
• 239000002904 solvent Substances 0.000 description 31
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 29
• 239000012267 brine Substances 0.000 description 27
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 27
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 26
• 239000007787 solid Substances 0.000 description 23
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 21
• 239000003921 oil Substances 0.000 description 21
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 19
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 16
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
• WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 13
• 239000007788 liquid Substances 0.000 description 13
• 238000000746 purification Methods 0.000 description 13
• XGNKBJVXMQZUEB-UHFFFAOYSA-N 1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCNCC2)C(=O)N(CC(C)C)C1=O XGNKBJVXMQZUEB-UHFFFAOYSA-N 0.000 description 12
• ZPFVZUKLAUKYSK-UHFFFAOYSA-N 1-benzyl-4-[2-(4-methoxyphenyl)ethylamino]piperidine-4-carbonitrile Chemical compound C1=CC(OC)=CC=C1CCNC1(C#N)CCN(CC=2C=CC=CC=2)CC1 ZPFVZUKLAUKYSK-UHFFFAOYSA-N 0.000 description 11
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 11
• 239000002253 acid Substances 0.000 description 11
• 229920006395 saturated elastomer Polymers 0.000 description 11
• 239000002585 base Substances 0.000 description 10
• 210000004027 cell Anatomy 0.000 description 10
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
• 238000002360 preparation method Methods 0.000 description 9
• 125000003118 aryl group Chemical group 0.000 description 8
• 238000004587 chromatography analysis Methods 0.000 description 8
• ZTBCOZQPDZZCJO-UHFFFAOYSA-N methyl 2-(3-bromophenyl)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)C1=CC=CC(Br)=C1 ZTBCOZQPDZZCJO-UHFFFAOYSA-N 0.000 description 8
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 8
• 238000010992 reflux Methods 0.000 description 8
• IUQYZZLJRJUKIH-UHFFFAOYSA-N tert-butyl 2-(3-bromophenyl)acetate Chemical compound CC(C)(C)OC(=O)CC1=CC=CC(Br)=C1 IUQYZZLJRJUKIH-UHFFFAOYSA-N 0.000 description 8
• JLZBBYOGYFIQKJ-UHFFFAOYSA-N 8-benzyl-1-[2-(4-methoxyphenyl)ethyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC=3C=CC=CC=3)CC2)C(=O)NC1=O JLZBBYOGYFIQKJ-UHFFFAOYSA-N 0.000 description 7
• 239000003795 chemical substances by application Substances 0.000 description 7
• 125000005843 halogen group Chemical group 0.000 description 7
• 239000000377 silicon dioxide Substances 0.000 description 7
• 238000003756 stirring Methods 0.000 description 7
• KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 6
• LTPVSOCPYWDIFU-UHFFFAOYSA-N 4-methoxyphenylethylamine Chemical compound COC1=CC=C(CCN)C=C1 LTPVSOCPYWDIFU-UHFFFAOYSA-N 0.000 description 6
• 150000001204 N-oxides Chemical class 0.000 description 6
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
• 239000012230 colorless oil Substances 0.000 description 6
• 238000004007 reversed phase HPLC Methods 0.000 description 6
• 239000000725 suspension Substances 0.000 description 6
• 229940124597 therapeutic agent Drugs 0.000 description 6
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
• BWDWWCUWLXSDPC-UHFFFAOYSA-N 1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-1,3,9-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CNCCC2)C(=O)N(CC(C)C)C1=O BWDWWCUWLXSDPC-UHFFFAOYSA-N 0.000 description 5
• FPWYTTVTKOXQCA-UHFFFAOYSA-N 8-benzyl-1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC=3C=CC=CC=3)CC2)C(=O)N(CC(C)C)C1=O FPWYTTVTKOXQCA-UHFFFAOYSA-N 0.000 description 5
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
• LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
• 125000001309 chloro group Chemical group Cl* 0.000 description 5
• WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical compound O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 description 5
• WJUMYPRGOJRUPT-UHFFFAOYSA-N methyl 2-(2-chloropyrimidin-4-yl)oxy-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=NC(Cl)=N1 WJUMYPRGOJRUPT-UHFFFAOYSA-N 0.000 description 5
• 238000012360 testing method Methods 0.000 description 5
• 229940086542 triethylamine Drugs 0.000 description 5
• 0 *C(Cc1cccc(NCCC(CC=C)(C(N2CC3CCC3)=O)NC2O)c1)=O Chemical compound *C(Cc1cccc(NCCC(CC=C)(C(N2CC3CCC3)=O)NC2O)c1)=O 0.000 description 4
• CLTIMCXGBQJJIQ-UHFFFAOYSA-N 2-(3-bromo-5-methylphenyl)acetic acid Chemical compound CC1=CC(Br)=CC(CC(O)=O)=C1 CLTIMCXGBQJJIQ-UHFFFAOYSA-N 0.000 description 4
• TYROANKALFUMPQ-UHFFFAOYSA-N 3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-8-(3-hydroxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound OC1=CC=CC(C2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 TYROANKALFUMPQ-UHFFFAOYSA-N 0.000 description 4
• RTQUOAVIBPUYMH-UHFFFAOYSA-N 3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-8-(3-methoxyphenyl)-1,3-diazaspiro[4.5]decane-2,4-dione Chemical compound COC1=CC=CC(C2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C(=CC(Cl)=CC=2)Cl)=O)=C1 RTQUOAVIBPUYMH-UHFFFAOYSA-N 0.000 description 4
• LVYTXTPRGASLLK-UHFFFAOYSA-N 8-(3-methoxyphenyl)-1,4-dioxaspiro[4.5]dec-7-ene Chemical compound COC1=CC=CC(C=2CCC3(CC=2)OCCO3)=C1 LVYTXTPRGASLLK-UHFFFAOYSA-N 0.000 description 4
• KSUKOFTWYZLRTO-UHFFFAOYSA-N 8-(3-methoxyphenyl)-1,4-dioxaspiro[4.5]decan-8-ol Chemical compound COC1=CC=CC(C2(O)CCC3(CC2)OCCO3)=C1 KSUKOFTWYZLRTO-UHFFFAOYSA-N 0.000 description 4
• SRIVLESDLYTOAA-UHFFFAOYSA-N 9-benzyl-1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-1,3,9-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CN(CC=3C=CC=CC=3)CCC2)C(=O)N(CC(C)C)C1=O SRIVLESDLYTOAA-UHFFFAOYSA-N 0.000 description 4
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
• XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
• 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 4
• 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
• 108060001084 Luciferase Proteins 0.000 description 4
• 239000005089 Luciferase Substances 0.000 description 4
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
• PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
• 235000011114 ammonium hydroxide Nutrition 0.000 description 4
• FLHFTXCMKFVKRP-UHFFFAOYSA-N bromomethylcyclobutane Chemical compound BrCC1CCC1 FLHFTXCMKFVKRP-UHFFFAOYSA-N 0.000 description 4
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
• 229910000024 caesium carbonate Inorganic materials 0.000 description 4
• 150000001721 carbon Chemical group 0.000 description 4
• 230000003197 catalytic effect Effects 0.000 description 4
• 239000002552 dosage form Substances 0.000 description 4
• MFDZGDBPQSJAIC-UHFFFAOYSA-N ethyl 2-(2-chloropyridin-4-yl)acetate Chemical compound CCOC(=O)CC1=CC=NC(Cl)=C1 MFDZGDBPQSJAIC-UHFFFAOYSA-N 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 238000003818 flash chromatography Methods 0.000 description 4
• 238000009472 formulation Methods 0.000 description 4
• 239000011521 glass Substances 0.000 description 4
• 229910052736 halogen Inorganic materials 0.000 description 4
• 150000002367 halogens Chemical class 0.000 description 4
• ULSSGHADTSRELG-UHFFFAOYSA-N methyl 2-(3-bromophenyl)acetate Chemical compound COC(=O)CC1=CC=CC(Br)=C1 ULSSGHADTSRELG-UHFFFAOYSA-N 0.000 description 4
• 229910000027 potassium carbonate Inorganic materials 0.000 description 4
• 230000008569 process Effects 0.000 description 4
• 125000006239 protecting group Chemical group 0.000 description 4
• 239000007858 starting material Substances 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• LEIMLDGFXIOXMT-UHFFFAOYSA-N trimethylsilyl cyanide Chemical compound C[Si](C)(C)C#N LEIMLDGFXIOXMT-UHFFFAOYSA-N 0.000 description 4
• OPQTXIFYLGAFGD-UHFFFAOYSA-N 1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCNCC2)CN(CC(C)C)C1=O OPQTXIFYLGAFGD-UHFFFAOYSA-N 0.000 description 3
• HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 3
• BDSMXYHHKXXZBN-UHFFFAOYSA-N 1-bromo-3-(bromomethyl)-5-methylbenzene Chemical compound CC1=CC(Br)=CC(CBr)=C1 BDSMXYHHKXXZBN-UHFFFAOYSA-N 0.000 description 3
• ACTDHAVSXUXSGE-UHFFFAOYSA-N 2-(3-bromo-5-methylphenyl)acetonitrile Chemical compound CC1=CC(Br)=CC(CC#N)=C1 ACTDHAVSXUXSGE-UHFFFAOYSA-N 0.000 description 3
• MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 3
• DWBASXJXOOJROY-UHFFFAOYSA-N 4-(3-methoxyphenyl)cyclohexan-1-one Chemical compound COC1=CC=CC(C2CCC(=O)CC2)=C1 DWBASXJXOOJROY-UHFFFAOYSA-N 0.000 description 3
• KKFPXGXMSBBNJI-UHFFFAOYSA-N 5-chloro-2-methylphenol Chemical compound CC1=CC=C(Cl)C=C1O KKFPXGXMSBBNJI-UHFFFAOYSA-N 0.000 description 3
• PUOIFXVNOIXVJH-UHFFFAOYSA-N 8-(3-methoxyphenyl)-1,4-dioxaspiro[4.5]decane Chemical compound COC1=CC=CC(C2CCC3(CC2)OCCO3)=C1 PUOIFXVNOIXVJH-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• FLKJPTWUVKCZIR-UHFFFAOYSA-N 8-benzyl-4-hydroxy-1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC=3C=CC=CC=3)CC2)C(O)N(CC(C)C)C1=O FLKJPTWUVKCZIR-UHFFFAOYSA-N 0.000 description 3
• IJSUGDIEPJSFOK-UHFFFAOYSA-N 9-benzyl-1-[2-(4-methoxyphenyl)ethyl]-1,3,9-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CN(CC=3C=CC=CC=3)CCC2)C(=O)NC1=O IJSUGDIEPJSFOK-UHFFFAOYSA-N 0.000 description 3
• 229910018072 Al 2 O 3 Inorganic materials 0.000 description 3
• UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
• 229910052794 bromium Inorganic materials 0.000 description 3
• 125000001246 bromo group Chemical group Br* 0.000 description 3
• 229910052801 chlorine Inorganic materials 0.000 description 3
• WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 3
• 239000013058 crude material Substances 0.000 description 3
• 239000012043 crude product Substances 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 239000012458 free base Substances 0.000 description 3
• 229940091173 hydantoin Drugs 0.000 description 3
• 239000005457 ice water Substances 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 108020001756 ligand binding domains Proteins 0.000 description 3
• VLCDRPDNINRLNQ-UHFFFAOYSA-N methyl 2-(3-bromo-5-methylphenyl)acetate Chemical compound COC(=O)CC1=CC(C)=CC(Br)=C1 VLCDRPDNINRLNQ-UHFFFAOYSA-N 0.000 description 3
• ICLWUCSNDDYEAC-UHFFFAOYSA-N methyl 2-(3-chlorosulfonyl-4-methylphenyl)acetate Chemical compound COC(=O)CC1=CC=C(C)C(S(Cl)(=O)=O)=C1 ICLWUCSNDDYEAC-UHFFFAOYSA-N 0.000 description 3
• NYEYWFMQNOBQNA-UHFFFAOYSA-N methyl 2-(5-bromo-2-methylphenyl)acetate Chemical compound COC(=O)CC1=CC(Br)=CC=C1C NYEYWFMQNOBQNA-UHFFFAOYSA-N 0.000 description 3
• MKQGUCPIBZQIRP-UHFFFAOYSA-N methyl 2-[2-(chloromethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC=C1CCl MKQGUCPIBZQIRP-UHFFFAOYSA-N 0.000 description 3
• YPHYEUAIDAUFAH-UHFFFAOYSA-N methyl 2-[3-(bromomethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(CBr)=C1 YPHYEUAIDAUFAH-UHFFFAOYSA-N 0.000 description 3
• YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 3
• 239000013612 plasmid Substances 0.000 description 3
• 239000000741 silica gel Substances 0.000 description 3
• 229910002027 silica gel Inorganic materials 0.000 description 3
• 238000010898 silica gel chromatography Methods 0.000 description 3
• 229910000033 sodium borohydride Inorganic materials 0.000 description 3
• 239000012279 sodium borohydride Substances 0.000 description 3
• FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
• RYCUONWTESCKFZ-UHFFFAOYSA-N tert-butyl 2-[3-(4-oxopiperidin-1-yl)phenyl]acetate Chemical compound CC(C)(C)OC(=O)CC1=CC=CC(N2CCC(=O)CC2)=C1 RYCUONWTESCKFZ-UHFFFAOYSA-N 0.000 description 3
• FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 3
• 230000002103 transcriptional effect Effects 0.000 description 3
• 238000001890 transfection Methods 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
• VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 2
• JDNPUJCKXLOHOW-UHFFFAOYSA-N 1-(bromomethyl)-4-(trifluoromethoxy)benzene Chemical compound FC(F)(F)OC1=CC=C(CBr)C=C1 JDNPUJCKXLOHOW-UHFFFAOYSA-N 0.000 description 2
• UDXBPFMORNHOIV-UHFFFAOYSA-N 1-benzyl-3-[2-(4-methoxyphenyl)ethylamino]piperidine-3-carbonitrile Chemical compound C1=CC(OC)=CC=C1CCNC1(C#N)CN(CC=2C=CC=CC=2)CCC1 UDXBPFMORNHOIV-UHFFFAOYSA-N 0.000 description 2
• BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 2
• VHJKDOLGYMULOP-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)ethanamine Chemical compound NCCC1=CC=C(Cl)C=C1Cl VHJKDOLGYMULOP-UHFFFAOYSA-N 0.000 description 2
• MZVSTDHRRYQFGI-UHFFFAOYSA-N 2-chloro-4-methylpyridine Chemical compound CC1=CC=NC(Cl)=C1 MZVSTDHRRYQFGI-UHFFFAOYSA-N 0.000 description 2
• BWLBGMIXKSTLSX-UHFFFAOYSA-M 2-hydroxyisobutyrate Chemical compound CC(C)(O)C([O-])=O BWLBGMIXKSTLSX-UHFFFAOYSA-M 0.000 description 2
• MPIKRRVLEVALBO-UHFFFAOYSA-N 3-(cyclopropylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCNCC2)C(=O)N(CC2CC2)C1=O MPIKRRVLEVALBO-UHFFFAOYSA-N 0.000 description 2
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
• WJYDPBGFOYOKLX-UHFFFAOYSA-N 4-bromo-1-methyl-2-(2,2,2-trichloroethyl)benzene Chemical compound CC1=CC=C(Br)C=C1CC(Cl)(Cl)Cl WJYDPBGFOYOKLX-UHFFFAOYSA-N 0.000 description 2
• UEVFFMZHGNYDKM-UHFFFAOYSA-N 5-bromo-2-chlorophenol Chemical compound OC1=CC(Br)=CC=C1Cl UEVFFMZHGNYDKM-UHFFFAOYSA-N 0.000 description 2
• RXQNKKRGJJRMKD-UHFFFAOYSA-N 5-bromo-2-methylaniline Chemical compound CC1=CC=C(Br)C=C1N RXQNKKRGJJRMKD-UHFFFAOYSA-N 0.000 description 2
• GZAZGBSQKXTNME-UHFFFAOYSA-N 8-benzyl-3-(cyclopropylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC=3C=CC=CC=3)CC2)C(=O)N(CC2CC2)C1=O GZAZGBSQKXTNME-UHFFFAOYSA-N 0.000 description 2
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
• 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
• 102100039556 Galectin-4 Human genes 0.000 description 2
• 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 2
• 241000124008 Mammalia Species 0.000 description 2
• MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
• WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
• 229920002472 Starch Polymers 0.000 description 2
• RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
• 108090000631 Trypsin Proteins 0.000 description 2
• 102000004142 Trypsin Human genes 0.000 description 2
• 239000002250 absorbent Substances 0.000 description 2
• 230000002745 absorbent Effects 0.000 description 2
• 239000013543 active substance Substances 0.000 description 2
• 229910052786 argon Inorganic materials 0.000 description 2
• 238000003556 assay Methods 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 239000008280 blood Substances 0.000 description 2
• 210000004369 blood Anatomy 0.000 description 2
• ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
• AEILLAXRDHDKDY-UHFFFAOYSA-N bromomethylcyclopropane Chemical compound BrCC1CC1 AEILLAXRDHDKDY-UHFFFAOYSA-N 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 229910002091 carbon monoxide Inorganic materials 0.000 description 2
• 239000003054 catalyst Substances 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000001276 controlling effect Effects 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000003085 diluting agent Substances 0.000 description 2
• VZARWHJHIUIKHF-UHFFFAOYSA-N ethyl 2-[3-(bromomethyl)phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(CBr)=C1 VZARWHJHIUIKHF-UHFFFAOYSA-N 0.000 description 2
• 238000001704 evaporation Methods 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 238000001914 filtration Methods 0.000 description 2
• 239000000499 gel Substances 0.000 description 2
• 125000001188 haloalkyl group Chemical group 0.000 description 2
• 125000001072 heteroaryl group Chemical group 0.000 description 2
• 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 150000007529 inorganic bases Chemical class 0.000 description 2
• 230000003993 interaction Effects 0.000 description 2
• 125000002346 iodo group Chemical group I* 0.000 description 2
• OSCZGJZRPUUPFJ-UHFFFAOYSA-N methyl 2-(4-chloropyrimidin-2-yl)oxy-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=NC=CC(Cl)=N1 OSCZGJZRPUUPFJ-UHFFFAOYSA-N 0.000 description 2
• LPMCIMPPZVHJSX-UHFFFAOYSA-N methyl 2-(5-chloro-2-methylphenoxy)acetate Chemical compound COC(=O)COC1=CC(Cl)=CC=C1C LPMCIMPPZVHJSX-UHFFFAOYSA-N 0.000 description 2
• IEQFGXLJQCZRNZ-UHFFFAOYSA-N methyl 2-[3-(bromomethyl)phenyl]propanoate Chemical compound COC(=O)C(C)C1=CC=CC(CBr)=C1 IEQFGXLJQCZRNZ-UHFFFAOYSA-N 0.000 description 2
• YNMVGYGTTHLQRA-UHFFFAOYSA-N methyl 2-[3-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]sulfonyl]-4-methylphenyl]acetate Chemical compound COC(=O)CC1=CC=C(C)C(S(=O)(=O)N2CCC3(CC2)C(N(CC(C)C)C(=O)N3CCC=2C=CC(OC)=CC=2)=O)=C1 YNMVGYGTTHLQRA-UHFFFAOYSA-N 0.000 description 2
• 238000002156 mixing Methods 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• 125000002950 monocyclic group Chemical group 0.000 description 2
• SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
• 229910052757 nitrogen Inorganic materials 0.000 description 2
• 239000012299 nitrogen atmosphere Substances 0.000 description 2
• 239000002674 ointment Substances 0.000 description 2
• 150000007530 organic bases Chemical class 0.000 description 2
• 239000003960 organic solvent Substances 0.000 description 2
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
• 125000003386 piperidinyl group Chemical group 0.000 description 2
• 239000003755 preservative agent Substances 0.000 description 2
• 239000000047 product Substances 0.000 description 2
• 238000001953 recrystallisation Methods 0.000 description 2
• 230000004044 response Effects 0.000 description 2
• 239000003381 stabilizer Substances 0.000 description 2
• 239000008107 starch Substances 0.000 description 2
• 235000019698 starch Nutrition 0.000 description 2
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
• 239000000829 suppository Substances 0.000 description 2
• VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
• 239000012588 trypsin Substances 0.000 description 2
• SYOKIDBDQMKNDQ-XWTIBIIYSA-N vildagliptin Chemical compound C1C(O)(C2)CC(C3)CC1CC32NCC(=O)N1CCC[C@H]1C#N SYOKIDBDQMKNDQ-XWTIBIIYSA-N 0.000 description 2
• ZSOPWZQRZHWYFY-NUXPJIRBSA-N (2s,3s)-2-amino-3-methyl-1-(1,3-thiazolidin-3-yl)pentan-1-one;(e)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.CC[C@H](C)[C@H](N)C(=O)N1CCSC1 ZSOPWZQRZHWYFY-NUXPJIRBSA-N 0.000 description 1
• ZGGHKIMDNBDHJB-RPQBTBOMSA-M (3S,5R)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-RPQBTBOMSA-M 0.000 description 1
• 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
• FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
• KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
• XDAGZUGDGORLMZ-UHFFFAOYSA-N 1-benzylpiperidin-3-one;hydrate;hydrochloride Chemical compound O.Cl.C1C(=O)CCCN1CC1=CC=CC=C1 XDAGZUGDGORLMZ-UHFFFAOYSA-N 0.000 description 1
• SJZKULRDWHPHGG-UHFFFAOYSA-N 1-benzylpiperidin-4-one Chemical compound C1CC(=O)CCN1CC1=CC=CC=C1 SJZKULRDWHPHGG-UHFFFAOYSA-N 0.000 description 1
• PLDWAJLZAAHOGG-UHFFFAOYSA-N 1-bromo-3-methoxybenzene Chemical compound COC1=CC=CC(Br)=C1 PLDWAJLZAAHOGG-UHFFFAOYSA-N 0.000 description 1
• BTUGGGLMQBJCBN-UHFFFAOYSA-N 1-iodo-2-methylpropane Chemical compound CC(C)CI BTUGGGLMQBJCBN-UHFFFAOYSA-N 0.000 description 1
• HGUFODBRKLSHSI-UHFFFAOYSA-N 2,3,7,8-tetrachloro-dibenzo-p-dioxin Chemical compound O1C2=CC(Cl)=C(Cl)C=C2OC2=C1C=C(Cl)C(Cl)=C2 HGUFODBRKLSHSI-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 1
• OEPOKWHJYJXUGD-UHFFFAOYSA-N 2-(3-phenylmethoxyphenyl)-1,3-thiazole-4-carbaldehyde Chemical compound O=CC1=CSC(C=2C=C(OCC=3C=CC=CC=3)C=CC=2)=N1 OEPOKWHJYJXUGD-UHFFFAOYSA-N 0.000 description 1
• BBHBUJQFVCMESB-UHFFFAOYSA-N 2-(5-bromo-2-methoxyphenyl)acetic acid Chemical compound COC1=CC=C(Br)C=C1CC(O)=O BBHBUJQFVCMESB-UHFFFAOYSA-N 0.000 description 1
• NOKLOLLCDCEFAK-UHFFFAOYSA-N 2-(5-chloro-2-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC=C1F NOKLOLLCDCEFAK-UHFFFAOYSA-N 0.000 description 1
• IUVCFHHAEHNCFT-INIZCTEOSA-N 2-[(1s)-1-[4-amino-3-(3-fluoro-4-propan-2-yloxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]ethyl]-6-fluoro-3-(3-fluorophenyl)chromen-4-one Chemical compound C1=C(F)C(OC(C)C)=CC=C1C(C1=C(N)N=CN=C11)=NN1[C@@H](C)C1=C(C=2C=C(F)C=CC=2)C(=O)C2=CC(F)=CC=C2O1 IUVCFHHAEHNCFT-INIZCTEOSA-N 0.000 description 1
• HRVXDMIQGGJIIN-UHFFFAOYSA-N 2-[3-[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenoxy]-2-methylpropanoic acid Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(OC(C)(C)C(O)=O)C=CC=2)C(=O)N(CC(C)C)C1=O HRVXDMIQGGJIIN-UHFFFAOYSA-N 0.000 description 1
• QQXBRVQJMKBAOZ-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]propanoic acid Chemical compound OC(=O)C(C)C1=CC=C(CBr)C=C1 QQXBRVQJMKBAOZ-UHFFFAOYSA-N 0.000 description 1
• SKUSNIXIBFEGSU-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]ethyl methanesulfonate Chemical compound CS(=O)(=O)OCCC1=CC=C(C(F)(F)F)C=C1 SKUSNIXIBFEGSU-UHFFFAOYSA-N 0.000 description 1
• GINCGCMLTQDEJC-UHFFFAOYSA-N 2-[5-chloro-2-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC=C1C(F)(F)F GINCGCMLTQDEJC-UHFFFAOYSA-N 0.000 description 1
• GXZDYRYYNXYPMQ-UHFFFAOYSA-N 2-chloro-6-methylpyridine Chemical compound CC1=CC=CC(Cl)=N1 GXZDYRYYNXYPMQ-UHFFFAOYSA-N 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
• WHNQTHDJEZTVHS-UHFFFAOYSA-N 3-(1,3-benzothiazol-2-yl)propanoic acid Chemical compound C1=CC=C2SC(CCC(=O)O)=NC2=C1 WHNQTHDJEZTVHS-UHFFFAOYSA-N 0.000 description 1
• DWKWMFSWLCIMKI-UHFFFAOYSA-N 3-(3-bromophenyl)propanoic acid Chemical compound OC(=O)CCC1=CC=CC(Br)=C1 DWKWMFSWLCIMKI-UHFFFAOYSA-N 0.000 description 1
• XCMQDLOYRWXZBR-UHFFFAOYSA-N 3-(cyclobutylmethyl)-1-[2-(2,4-dichlorophenyl)ethyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound ClC1=CC(Cl)=CC=C1CCN1C2(CCNCC2)C(=O)N(CC2CCC2)C1=O XCMQDLOYRWXZBR-UHFFFAOYSA-N 0.000 description 1
• 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
• NTHGIYFSMNNHSC-UHFFFAOYSA-N 3-methylbutyl nitrate Chemical compound CC(C)CCO[N+]([O-])=O NTHGIYFSMNNHSC-UHFFFAOYSA-N 0.000 description 1
• XHKXPBBVNFCGOD-UHFFFAOYSA-N 3-propyl-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound C1CNCCC21C(=O)N(CCC)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 XHKXPBBVNFCGOD-UHFFFAOYSA-N 0.000 description 1
• XJPZKYIHCLDXST-UHFFFAOYSA-N 4,6-dichloropyrimidine Chemical compound ClC1=CC(Cl)=NC=N1 XJPZKYIHCLDXST-UHFFFAOYSA-N 0.000 description 1
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
• 125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 1
• QAHCQGXGAYRHHW-UHFFFAOYSA-N 5-bromo-2,3-difluorophenol Chemical compound OC1=CC(Br)=CC(F)=C1F QAHCQGXGAYRHHW-UHFFFAOYSA-N 0.000 description 1
• OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 239000004342 Benzoyl peroxide Substances 0.000 description 1
• OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
• 230000004568 DNA-binding Effects 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• OIFBSDVPJOWBCH-UHFFFAOYSA-N Diethyl carbonate Chemical compound CCOC(=O)OCC OIFBSDVPJOWBCH-UHFFFAOYSA-N 0.000 description 1
• 108010010803 Gelatin Proteins 0.000 description 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
• 239000012448 Lithium borohydride Substances 0.000 description 1
• FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• PHSPJQZRQAJPPF-UHFFFAOYSA-N N-alpha-Methylhistamine Chemical compound CNCCC1=CN=CN1 PHSPJQZRQAJPPF-UHFFFAOYSA-N 0.000 description 1
• 125000000815 N-oxide group Chemical group 0.000 description 1
• QOVYHDHLFPKQQG-NDEPHWFRSA-N N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O Chemical compound N[C@@H](CCC(=O)N1CCC(CC1)NC1=C2C=CC=CC2=NC(NCC2=CN(CCCNCCCNC3CCCCC3)N=N2)=N1)C(O)=O QOVYHDHLFPKQQG-NDEPHWFRSA-N 0.000 description 1
• 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
• OLXTXUKAYZUFJY-UHFFFAOYSA-N OC(CC(C=CC1)=CC1N(CC1)CCC1(C(N(CC1CCC1)C1)=O)N1O)=O Chemical compound OC(CC(C=CC1)=CC1N(CC1)CCC1(C(N(CC1CCC1)C1)=O)N1O)=O OLXTXUKAYZUFJY-UHFFFAOYSA-N 0.000 description 1
• 229930182555 Penicillin Natural products 0.000 description 1
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
• 239000002202 Polyethylene glycol Substances 0.000 description 1
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
• 229910004298 SiO 2 Inorganic materials 0.000 description 1
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
• 235000021355 Stearic acid Nutrition 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102000040945 Transcription factor Human genes 0.000 description 1
• 108091023040 Transcription factor Proteins 0.000 description 1
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
• 150000007513 acids Chemical class 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 230000032683 aging Effects 0.000 description 1
• 239000000556 agonist Substances 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
• 239000000908 ammonium hydroxide Substances 0.000 description 1
• 239000007864 aqueous solution Substances 0.000 description 1
• 239000003125 aqueous solvent Substances 0.000 description 1
• 125000000732 arylene group Chemical group 0.000 description 1
• 239000012131 assay buffer Substances 0.000 description 1
• 239000012911 assay medium Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
• 235000019400 benzoyl peroxide Nutrition 0.000 description 1
• WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
• 230000027455 binding Effects 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000009835 boiling Methods 0.000 description 1
• ZMCUDHNSHCRDBT-UHFFFAOYSA-M caesium bicarbonate Chemical compound [Cs+].OC([O-])=O ZMCUDHNSHCRDBT-UHFFFAOYSA-M 0.000 description 1
• 159000000007 calcium salts Chemical class 0.000 description 1
• 239000002775 capsule Substances 0.000 description 1
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
• 239000001768 carboxy methyl cellulose Substances 0.000 description 1
• 230000006037 cell lysis Effects 0.000 description 1
• 239000001913 cellulose Substances 0.000 description 1
• 229920002678 cellulose Polymers 0.000 description 1
• 239000003610 charcoal Substances 0.000 description 1
• KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
• 239000003638 chemical reducing agent Substances 0.000 description 1
• XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
• 238000003776 cleavage reaction Methods 0.000 description 1
• 238000011260 co-administration Methods 0.000 description 1
• 238000000576 coating method Methods 0.000 description 1
• 239000003086 colorant Substances 0.000 description 1
• 239000012141 concentrate Substances 0.000 description 1
• 238000007796 conventional method Methods 0.000 description 1
• 238000001816 cooling Methods 0.000 description 1
• 239000010949 copper Substances 0.000 description 1
• ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 239000008121 dextrose Substances 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 239000007884 disintegrant Substances 0.000 description 1
• 239000006185 dispersion Substances 0.000 description 1
• 238000004090 dissolution Methods 0.000 description 1
• 231100000673 dose–response relationship Toxicity 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000003480 eluent Substances 0.000 description 1
• 239000003995 emulsifying agent Substances 0.000 description 1
• 239000000839 emulsion Substances 0.000 description 1
• RVIWPVAVHHVQIR-UHFFFAOYSA-N ethyl 2-(3-methylphenyl)acetate Chemical compound CCOC(=O)CC1=CC=CC(C)=C1 RVIWPVAVHHVQIR-UHFFFAOYSA-N 0.000 description 1
• VVNIIEKVHWJFQJ-UHFFFAOYSA-N ethyl 2-(6-chloropyridin-2-yl)acetate Chemical compound CCOC(=O)CC1=CC=CC(Cl)=N1 VVNIIEKVHWJFQJ-UHFFFAOYSA-N 0.000 description 1
• MZIGCDPKRWBPMT-UHFFFAOYSA-N ethyl 2-[3-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]methyl]phenyl]acetate Chemical compound CCOC(=O)CC1=CC=CC(CN2CCC3(CC2)C(N(CC(C)C)C(=O)N3CCC=2C=CC(OC)=CC=2)=O)=C1 MZIGCDPKRWBPMT-UHFFFAOYSA-N 0.000 description 1
• OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
• PQVSTLUFSYVLTO-UHFFFAOYSA-N ethyl n-ethoxycarbonylcarbamate Chemical compound CCOC(=O)NC(=O)OCC PQVSTLUFSYVLTO-UHFFFAOYSA-N 0.000 description 1
• 238000002474 experimental method Methods 0.000 description 1
• 239000013604 expression vector Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 239000000796 flavoring agent Substances 0.000 description 1
• 235000019634 flavors Nutrition 0.000 description 1
• 125000001153 fluoro group Chemical group F* 0.000 description 1
• 235000003599 food sweetener Nutrition 0.000 description 1
• 239000013022 formulation composition Substances 0.000 description 1
• 238000005194 fractionation Methods 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 210000001035 gastrointestinal tract Anatomy 0.000 description 1
• 239000008273 gelatin Substances 0.000 description 1
• 229920000159 gelatin Polymers 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 235000019322 gelatine Nutrition 0.000 description 1
• 235000011852 gelatine desserts Nutrition 0.000 description 1
• 230000014509 gene expression Effects 0.000 description 1
• 230000036541 health Effects 0.000 description 1
• 125000005842 heteroatom Chemical group 0.000 description 1
• SXWRTZOXMUOJER-UHFFFAOYSA-N hydron;piperidin-4-one;chloride;hydrate Chemical compound O.Cl.O=C1CCNCC1 SXWRTZOXMUOJER-UHFFFAOYSA-N 0.000 description 1
• 229940126904 hypoglycaemic agent Drugs 0.000 description 1
• 125000002883 imidazolyl group Chemical group 0.000 description 1
• 238000001727 in vivo Methods 0.000 description 1
• 238000011534 incubation Methods 0.000 description 1
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000002401 inhibitory effect Effects 0.000 description 1
• 239000007972 injectable composition Substances 0.000 description 1
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
• IQZZFVDIZRWADY-UHFFFAOYSA-N isocoumarin Chemical compound C1=CC=C2C(=O)OC=CC2=C1 IQZZFVDIZRWADY-UHFFFAOYSA-N 0.000 description 1
• 239000000644 isotonic solution Substances 0.000 description 1
• 125000000842 isoxazolyl group Chemical group 0.000 description 1
• 150000002576 ketones Chemical class 0.000 description 1
• 210000003292 kidney cell Anatomy 0.000 description 1
• 239000008101 lactose Substances 0.000 description 1
• GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium hydroxide monohydrate Substances [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
• 229940040692 lithium hydroxide monohydrate Drugs 0.000 description 1
• 239000006210 lotion Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
• 238000004020 luminiscence type Methods 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• 229910052749 magnesium Inorganic materials 0.000 description 1
• 210000004962 mammalian cell Anatomy 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000000463 material Substances 0.000 description 1
• 239000011159 matrix material Substances 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 238000002844 melting Methods 0.000 description 1
• 230000008018 melting Effects 0.000 description 1
• HVILJIWAXWZQQW-UHFFFAOYSA-N methyl 2-(3-bromophenoxy)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC=CC(Br)=C1 HVILJIWAXWZQQW-UHFFFAOYSA-N 0.000 description 1
• MYPHYUYCJZVEDV-UHFFFAOYSA-N methyl 2-(3-bromophenoxy)acetate Chemical compound COC(=O)COC1=CC=CC(Br)=C1 MYPHYUYCJZVEDV-UHFFFAOYSA-N 0.000 description 1
• JQZHPLYYKVFFIF-UHFFFAOYSA-N methyl 2-(3-chlorosulfonyl-4-methoxyphenyl)acetate Chemical compound COC(=O)CC1=CC=C(OC)C(S(Cl)(=O)=O)=C1 JQZHPLYYKVFFIF-UHFFFAOYSA-N 0.000 description 1
• LSAGWGNECLEVPE-UHFFFAOYSA-N methyl 2-(4-methylphenyl)acetate Chemical compound COC(=O)CC1=CC=C(C)C=C1 LSAGWGNECLEVPE-UHFFFAOYSA-N 0.000 description 1
• HUXKDUZLHQWKIG-UHFFFAOYSA-N methyl 2-(5-bromo-2,3-difluorophenoxy)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC(Br)=CC(F)=C1F HUXKDUZLHQWKIG-UHFFFAOYSA-N 0.000 description 1
• CLFVNODVIPRUIK-UHFFFAOYSA-N methyl 2-(5-bromo-2-chlorophenoxy)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC(Br)=CC=C1Cl CLFVNODVIPRUIK-UHFFFAOYSA-N 0.000 description 1
• ZWSAANYJMPECGB-UHFFFAOYSA-N methyl 2-(5-bromo-2-chlorophenoxy)acetate Chemical compound COC(=O)COC1=CC(Br)=CC=C1Cl ZWSAANYJMPECGB-UHFFFAOYSA-N 0.000 description 1
• CDWQAOTZAMADBL-UHFFFAOYSA-N methyl 2-(5-bromo-2-methoxyphenyl)acetate Chemical compound COC(=O)CC1=CC(Br)=CC=C1OC CDWQAOTZAMADBL-UHFFFAOYSA-N 0.000 description 1
• WWOSVKYMYNEUEP-UHFFFAOYSA-N methyl 2-(5-chloro-2-fluorophenyl)acetate Chemical compound COC(=O)CC1=CC(Cl)=CC=C1F WWOSVKYMYNEUEP-UHFFFAOYSA-N 0.000 description 1
• GNLONBSRIADEKC-UHFFFAOYSA-N methyl 2-(5-chloro-2-methylphenoxy)-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC(Cl)=CC=C1C GNLONBSRIADEKC-UHFFFAOYSA-N 0.000 description 1
• ICNYMKVPKLKYLO-UHFFFAOYSA-N methyl 2-(6-chloropyrimidin-4-yl)oxy-2-methylpropanoate Chemical compound COC(=O)C(C)(C)OC1=CC(Cl)=NC=N1 ICNYMKVPKLKYLO-UHFFFAOYSA-N 0.000 description 1
• OXFCILAOEGBINA-UHFFFAOYSA-N methyl 2-[4-(bromomethyl)phenyl]propanoate Chemical compound COC(=O)C(C)C1=CC=C(CBr)C=C1 OXFCILAOEGBINA-UHFFFAOYSA-N 0.000 description 1
• WIHKJSCZLCYPMN-UHFFFAOYSA-N methyl 2-[4-[[1-[2-(4-methoxyphenyl)ethyl]-3-(2-methylpropyl)-2,4-dioxo-1,3-diazaspiro[4.5]decan-7-yl]methyl]phenyl]propanoate Chemical compound C1=CC(C(C)C(=O)OC)=CC=C1CC1CC2(C(N(CC(C)C)C(=O)N2CCC=2C=CC(OC)=CC=2)=O)CCC1 WIHKJSCZLCYPMN-UHFFFAOYSA-N 0.000 description 1
• VGAOAXNTOKIFSH-UHFFFAOYSA-N methyl 2-[5-chloro-2-(trifluoromethyl)phenyl]acetate Chemical compound COC(=O)CC1=CC(Cl)=CC=C1C(F)(F)F VGAOAXNTOKIFSH-UHFFFAOYSA-N 0.000 description 1
• PQUSVJVVRXWKDG-UHFFFAOYSA-N methyl 2-bromo-2-methylpropanoate Chemical compound COC(=O)C(C)(C)Br PQUSVJVVRXWKDG-UHFFFAOYSA-N 0.000 description 1
• DJJHVPBMUQLOCB-UHFFFAOYSA-N methyl 3-(3-bromophenyl)propanoate Chemical compound COC(=O)CCC1=CC=CC(Br)=C1 DJJHVPBMUQLOCB-UHFFFAOYSA-N 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 150000004702 methyl esters Chemical class 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• ZHCAAFJSYLFLPX-UHFFFAOYSA-N nitrocyclohexatriene Chemical group [O-][N+](=O)C1=CC=C=C[CH]1 ZHCAAFJSYLFLPX-UHFFFAOYSA-N 0.000 description 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
• QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
• OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 230000003204 osmotic effect Effects 0.000 description 1
• 125000002971 oxazolyl group Chemical group 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 1
• 239000006072 paste Substances 0.000 description 1
• 229940049954 penicillin Drugs 0.000 description 1
• 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
• 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
• 150000003003 phosphines Chemical class 0.000 description 1
• FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
• 230000000704 physical effect Effects 0.000 description 1
• 125000004193 piperazinyl group Chemical group 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229920001223 polyethylene glycol Polymers 0.000 description 1
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 230000001681 protective effect Effects 0.000 description 1
• 125000003226 pyrazolyl group Chemical group 0.000 description 1
• 125000004076 pyridyl group Chemical group 0.000 description 1
• 125000000714 pyrimidinyl group Chemical group 0.000 description 1
• 238000010791 quenching Methods 0.000 description 1
• 230000000171 quenching effect Effects 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 230000006340 racemization Effects 0.000 description 1
• 150000003254 radicals Chemical class 0.000 description 1
• 230000009257 reactivity Effects 0.000 description 1
• 230000001105 regulatory effect Effects 0.000 description 1
• 239000011347 resin Substances 0.000 description 1
• 229920005989 resin Polymers 0.000 description 1
• 125000006413 ring segment Chemical group 0.000 description 1
• 238000007127 saponification reaction Methods 0.000 description 1
• 230000007017 scission Effects 0.000 description 1
• 230000001235 sensitizing effect Effects 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000012679 serum free medium Substances 0.000 description 1
• 235000015424 sodium Nutrition 0.000 description 1
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
• MNWBNISUBARLIT-UHFFFAOYSA-N sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
• 239000012312 sodium hydride Substances 0.000 description 1
• 229910000104 sodium hydride Inorganic materials 0.000 description 1
• 235000009518 sodium iodide Nutrition 0.000 description 1
• 159000000000 sodium salts Chemical class 0.000 description 1
• 239000011877 solvent mixture Substances 0.000 description 1
• 239000000600 sorbitol Substances 0.000 description 1
• 239000008117 stearic acid Substances 0.000 description 1
• 229960005322 streptomycin Drugs 0.000 description 1
• 239000000126 substance Substances 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 229910052717 sulfur Inorganic materials 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 239000012730 sustained-release form Substances 0.000 description 1
• 239000003765 sweetening agent Substances 0.000 description 1
• 239000000454 talc Substances 0.000 description 1
• 229910052623 talc Inorganic materials 0.000 description 1
• HLUWHCDBGMUJTQ-UHFFFAOYSA-N tert-butyl 2-[3-(2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl)phenyl]acetate Chemical compound CC(C)(C)OC(=O)CC1=CC=CC(N2CCC3(CC2)C(NC(=O)N3)=O)=C1 HLUWHCDBGMUJTQ-UHFFFAOYSA-N 0.000 description 1
• PIVDGSJPKSDVQN-UHFFFAOYSA-N tert-butyl 2-[3-[3-(2-methylpropyl)-2,4-dioxo-1-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetate Chemical compound C1CN(C=2C=C(CC(=O)OC(C)(C)C)C=CC=2)CCC21C(=O)N(CC(C)C)C(=O)N2CC1=CC=C(OC(F)(F)F)C=C1 PIVDGSJPKSDVQN-UHFFFAOYSA-N 0.000 description 1
• ZBSHEAWJWCSJBT-UHFFFAOYSA-N tert-butyl 2-[3-[3-(cyclobutylmethyl)-1-[4-(4-methoxyphenyl)butyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetate Chemical compound C1=CC(OC)=CC=C1CCCCN1C2(CCN(CC2)C=2C=C(CC(=O)OC(C)(C)C)C=CC=2)C(=O)N(CC2CCC2)C1=O ZBSHEAWJWCSJBT-UHFFFAOYSA-N 0.000 description 1
• KJHQRNAWHBGPBS-UHFFFAOYSA-N tert-butyl 2-[3-[3-(cyclobutylmethyl)-2,4-dioxo-1-[2-[4-(trifluoromethyl)phenyl]ethyl]-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetate Chemical compound CC(C)(C)OC(=O)CC1=CC=CC(N2CCC3(CC2)C(N(CC2CCC2)C(=O)N3CCC=2C=CC(=CC=2)C(F)(F)F)=O)=C1 KJHQRNAWHBGPBS-UHFFFAOYSA-N 0.000 description 1
• QGRWYSRFEIDHFN-UHFFFAOYSA-N tert-butyl 2-[3-[3-(cyclopropylmethyl)-1-[2-(4-methoxyphenyl)ethyl]-2,4-dioxo-1,3,8-triazaspiro[4.5]decan-8-yl]phenyl]acetate Chemical compound C1=CC(OC)=CC=C1CCN1C2(CCN(CC2)C=2C=C(CC(=O)OC(C)(C)C)C=CC=2)C(=O)N(CC2CC2)C1=O QGRWYSRFEIDHFN-UHFFFAOYSA-N 0.000 description 1
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
• 125000003831 tetrazolyl group Chemical group 0.000 description 1
• 238000011287 therapeutic dose Methods 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 125000001544 thienyl group Chemical group 0.000 description 1
• 239000012443 tonicity enhancing agent Substances 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• 238000003146 transient transfection Methods 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• 125000001425 triazolyl group Chemical group 0.000 description 1
• 238000005406 washing Methods 0.000 description 1
• 238000009736 wetting Methods 0.000 description 1
• 239000000080 wetting agent Substances 0.000 description 1
• ZXIBCJHYVWYIKI-PZJWPPBQSA-N ximelagatran Chemical compound C1([C@@H](NCC(=O)OCC)C(=O)N2[C@@H](CC2)C(=O)NCC=2C=CC(=CC=2)C(\N)=N\O)CCCCC1 ZXIBCJHYVWYIKI-PZJWPPBQSA-N 0.000 description 1
• 229960001522 ximelagatran Drugs 0.000 description 1
• 239000008096 xylene Substances 0.000 description 1